BofA analyst Tazeen Ahmad raised the firm’s price target on Annexon to $10 from $7 and keeps a Buy rating on the shares. The firm sees several near-term opportunities for upside with the upcoming readout of the phase 3 trial evaluating ANX005 in Guillain Barre syndrome, or GBS, in Q2 as well as initial proof of concept data from AN1502 in the second half of the year, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX:
- Annexon price target raised to $12 from $11 at Wells Fargo
- Annexon files $400M mixed securities shelf
- Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
- Annexon reports Q4 EPS (36c), consensus (44c)
- Annexon options imply 24.7% move in share price post-earnings
